protein

B18R Protein, Vaccinia virus (HEK293, His)

HY-P70015

2 μg;10 μg;50 μg

59;165;496 USD

B18R Protein, Vaccinia virus (HEK293, His)

proteins

HEK293

2 μg;10 μg;50 μg

59;165;496 USD

B18R protein functions as a potent antagonist against the antiviral effects of host IFN-alpha/beta and key IFN-inducible proteins, such as OAS1 involved in viral RNA degradation. It acts as a soluble IFN-alpha receptor, effectively impeding the interaction between host IFN-alpha and its receptor. The protein's ability to interact with host IFNA1 underscores its role in modulating the host's immune response against viral infections. B18R Protein, Vaccinia virus (HEK293, His) is the recombinant Virus-derived B18R protein, expressed by HEK293 , with C-6*His labeled tag. The total length of B18R Protein, Vaccinia virus (HEK293, His) is 332 a.a., with molecular weight of 46-65 kDa.

Virus

The B18R protein functions as a potent antagonist against the antiviral effects induced by host IFN-alpha/beta and key IFN-inducible proteins, including the host OAS1 involved in viral RNA degradation. Acting as a soluble IFN-alpha receptor, B18R inhibits the interaction between host IFN-alpha and its receptor. This interference in the IFN-alpha signaling pathway serves to counteract the host's innate immune response against viral infections. Notably, B18R achieves its inhibitory effects by interacting with host IFNA1. The multifaceted actions of B18R underscore its role as a viral immune evasion strategy, highlighting its importance in modulating the host's antiviral defenses.

rVaSoluble interferon alpha/beta receptor B18/VACWR200, His; Soluble interferon alpha/beta receptor B18; VACWR200

Greater than 95% as determined by reducing SDS-PAGE

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 or 20 mM PB, 150 mM NaCl, pH 7.4.

Room temperature in continental US; may vary elsewhere.